C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview

Area of Science:

• Oncology
• Molecular Biology
• Developmental Biology

Background:

• Pediatric tumors, though rare, are a major cause of childhood mortality in the US.
• The cellular-mesenchymal-epithelial transition (c-MET) pathway is crucial for normal development, regulating cell growth, survival, and invasive growth patterns.
• Aberrant MET signaling is implicated in the development and metastasis of various pediatric cancers, leading to poor patient prognosis.

Purpose of the Study:

• To review the significance of the c-MET/hepatocyte growth factor (HGF) signaling pathway in pediatric tumors.
• To discuss the role of aberrant MET signaling in pediatric carcinogenesis and metastasis.
• To summarize pre-clinical and clinical studies investigating inhibitors of this pathway for targeted therapy.

Main Methods:

• Literature review of pre-clinical and clinical studies.
• Analysis of the role of c-MET/HGF signaling in pediatric tumor development and progression.
• Examination of targeted therapeutic strategies.

Main Results:

• The c-MET/HGF pathway is fundamentally involved in the carcinogenesis of many pediatric tumors.
• Dysregulated MET signaling contributes to tumor metastasis and poor prognosis in pediatric cancer patients.
• Targeted inhibitors of the c-MET pathway show potential in pre-clinical and clinical settings.

Conclusions:

• The c-MET/HGF pathway is a critical target for precision medicine in pediatric oncology.
• Inhibitors of the c-MET pathway represent a promising therapeutic strategy for pediatric tumors.
• Further research and clinical trials are warranted to optimize targeted therapies for pediatric cancer patients.